Although preclinical studies have demonstrated that IL-2 can improve the efficacy of DC vaccines [85], subsequent clinical trials have failed to demonstrate an increase in anti-tumor immune responses through DC administration combined with IL-2 [67,86]. This evidence concerns the gene IL2 and neoplasm.